An observational study in Mayer Rokitansky Kuster Hauser Syndrome, sponsored by Imagine Institute. Recruiting at 2 sites in France. Per ClinicalTrials.gov, last updated 2018-10-12.
Sponsored by Imagine Institute · Observational
In order to understand the molecular mechanisms leading to Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), the research team has to identify molecular bases of this anomaly.
Toward this goal, the research team would like to include in the study patients with MRKH syndrome, as well as their healthy relatives, in order to perform genetic analyses, especially whole exome sequencing.
This study has been set up in order to collect biological samples from patients with MRKH and their relatives.
The MRKH is a congenital and rare malformation characterised by the absence of the uterus and of 2/3 of the vagina. The incidence is 1 in 4500 female children (46,XX) and a genetic component has been identified.
In order to understand the molecular mechanisms leading to this disease, the research team has to identify the genetic abnormalities.
This study will be led by the research team of the Imagine Institute and the clinical teams associated with the Reference Center for Rare Diseases PGR (Rare Gynecologic Diseases). Both groups are based on the Necker Hospital campus, and already closely collaborate on research into MRKH syndrome.
This collaboration will allow to :
i) collect biological samples from the propositus and their relatives,
ii) have a medical expertise.
The clinicians involved in the study will recruit patients, whose participation will involve providing a biological sample, ie, a blood sample and/or uterine tissue collected during surgical ablation, in the event that surgery is performed during clinical follow-up of the patients. No specific intervention will be planned for the purposes of this study.
In order to perform genetic analysis on trios, the healthy relatives of the patients (parents, brothers, sisters) will also be included. Blood samples will be taken once for healthy relatives.
Genetic analysis, especially whole exome sequencing, will be performed on blood samples by the research team of Imagine Institute.
9,217 studies on the registry are indexed under Syndrome; 1,031 are open to participants now.
This study's planned enrollment of 410 is above the median of 102 across 2,209 observational studies indexed under Syndrome.
Browse Syndrome studies →Imagine Institute is the lead sponsor of 30 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Recruitment of patients presenting MRKH syndrome, as well as their healthy relatives, in order to perform genetic analyses
Exclusion Criteria:
Biological samples for patients. Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study.
Genetic: Biological samples for patients
Biological samples for healthy relatives. Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)
Genetic: Biological samples for healthy relatives
Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
Blood samples.
Number of identified nucleotidic variation(s) whose consequences can explain the phenotype of MRKH syndrome
Genetic cause identification
Time frame: 15 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
46, XX Disorders of Sex Development
Imagine Institute